The Lancet publishes first clinical trial data of a fully bioabsorbable drug-eluting stent

These one year results for Abbott's bioabsorbable everolimus eluting stent were consistent with performance demonstrated by the system at 6 months, as previously reported in October 2007. Abbott's prospective, non-randomized, ABSORB clinical trial is designed to evaluate the overall safety and performance of a fully bioabsorbable everolimus eluting stent out to 5 years.

"Abbott's bioabsorbable everolimus eluting stent has demonstrated excellent clinical safety out to one year in patients with coronary artery disease," said Patrick W. Serruys, M.D., Ph.D., Professor of Interventional Cardiology at the Thoraxcentre, Erasmus University Hospital, Rotterdam, and co-principal investigator in the ABSORB study. "The positive results from this clinical trial form a strong basis for the development of additional bioabsorbable stent platforms with the potential to eliminate some of the restrictions posed by metallic stents in areas such as vessel imaging and vessel remodeling."

At 6 months, the overall MACE rate in the ABSORB trial was 3.3 percent (one patient, n=30) and late loss, a measure of reduction in vessel lumen diameter after stenting, was 0.44 mm. At one year, the overall MACE rate in the ABSORB trial was consistent with results at 6 months (one patient, 3.3 percent, n=30; 3.4 percent adjusted for one patient who withdrew from follow-up, known to be event free at 1 year, n=29). MACE is a composite measure of cardiac death, heart attack and re-treatment of a diseased lesion (ischemia-driven target lesion revascularization) in the ABSORB trial. Abbott's bioabsorbable everolimus eluting stent also demonstrated 100 percent procedural success and 94 percent device success in the ABSORB trial.

"Patients and physicians like the idea of a stent that does its job and is then absorbed away," said John A. Ormiston, M.B., Ch.B., cardiologist at Auckland City Hospital, in Auckland, New Zealand and principal investigator in the ABSORB trial. "Abbott's bioabsorbable stent has the potential to hold an artery open long enough for healing to occur, and we would expect an artery that is healed to function as it did before it became diseased."

Abbott is the only company with a fully bioabsorbable drug eluting coronary stent in clinical trials. Abbott’s bioabsorbable everolimus eluting coronary stent is made of polylactic acid, a proven biocompatible material that is commonly used in medical implants such as dissolvable sutures. As with a metallic stent, Abbott’s bioabsorbable stent is designed to restore blood flow in clogged coronary arteries, and to provide mechanical support until the blood vessel heals. Unlike a metallic stent, however, a bioabsorbable stent is designed to be slowly metabolized by the body and completely absorbed over time.

"Abbott's bioabsorbable drug eluting stent system is a great example of scientific innovation leading to a breakthrough treatment for heart disease that has the potential to improve patients' lives," said John M. Capek, Ph.D., executive vice president of medical devices, Abbott. "We look forward to continuing to evaluate the safety and effectiveness of our bioabsorbable stent platform in additional patients in the coming months."

Source: Abbott Laboratories

Don't ask, don't tell: Financial disclosure lacking in literature on stents
Most published research about coronary stents does not reveal information about authors’ financial relationships that might bias their interpretation of scientific data, according to researchers at Duke University Medical Center.
Drug-releasing stent shows promise for improving outcomes in patients with coronary artery disease
For patients who underwent angioplasty to open narrowed coronary arteries, the use of stents releasing the drug everolimus reduced the rate of renarrowing of the arteries and significantly reduced the risk of major cardiac events, compared to the widely-used paclitaxel-releasing stents, according to a study in the April 23/30 issue of JAMA.
Comparison of anticoagulants for angioplasty show similar outcomes
In a comparison of anticoagulants and stents for use with angioplasty following a heart attack, the anticoagulants abciximab and tirofiban had similar outcomes for some cardiac measures within 90 minutes after the procedure, while patients who received stents that released the drug sirolimus had a lower risk of major adverse cardiac events within 8 months than patients who received uncoated stents, according to a JAMA study being released early online March 30 to coincide with its presentation at the annual conference of the American College of Cardiology. The study will be published in the April 16 issue of JAMA.
Drug-eluting stents yield better outcomes than bare-metal ones
Drug-eluting stents are just as safe and effective as traditional bare-metal stents when used in routine clinical practice, according to a new study by researchers at Rhode Island Hospital. Their findings are published in the November 20th issue of the Journal of the American College of Cardiology.
Nanowire coating for bone implants, stents
University of Arkansas researchers have found a simple, inexpensive way to create a nanowire coating on the surface of biocompatible titanium that can be used to create more effective surfaces for hip replacement, dental reconstruction and vascular stenting. Further, the material can easily be sterilized using ultraviolet light and water or using ethanol, making it useful in hospital settings and meat-processing plants.
Nanowire Coating for Bone Implants, Stents
University of Arkansas researchers have found a simple, inexpensive way to create a nanowire coating on the surface of biocompatible titanium that can be used to create more effective surfaces for hip replacement, dental reconstruction and vascular stenting. Further, the material can easily be sterilized using ultraviolet light and water or using ethanol, making it useful in hospital settings and meat-processing plants.
Modified herpes virus keeps arteries 'free-flowing' following procedures
A genetically engineered herpes simplex virus, primarily known for causing cold sores, may help keep arteries “free-flowing” in the weeks following angioplasty or stent placement for patients, according to research published early in the online edition of PNAS (Proceedings of the National Academy of Sciences of the United States of America).
Regulated drug release thanks to nano bubbles
Stents are medical implants that, for example, prevent the blocking of arteries after surgery. One of the problems using stents is the biocompatibility as the human body rejects and attacks foreign material. The Forschungszentrum Dresden-Rossendorf (FZD) developed a new method for making the surface of metal stents highly nano porous by producing millions of nano bubbles underneath.

The Lancet publishes first clinical trial data of a fully bioabsorbable drug-eluting stent

Related stories:

News discussion: